APOTEX CORP. for APOTEX CORP.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs and their ingredients; Federal policy relating to amending the Hatch-Waxman Act to provide incentives for manufacturing generic pharmaceuticals and their ingredients in the United States and allied nations. Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; and Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Trade (domestic/foreign) TRD
Federal policy relating to the review of the United States-Mexico-Canada trade agreement and the North American generic drug supply chain; and Federal policy relating to the United States-Mexico-Canada trade agreements rules of origin requirements for pharmaceuticals.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Copyright/Patent/Trademark CPT
HR 6485/S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; HR 3269/S. 2276, the Eliminating Thickets to Increase Competition (ETHIC) Act, provisions relating to capping the number of patents that can be asserted against biosimilar and generic manufacturers to one per terminally disclaimed group; Federal policy relating to the Patent and Trademark Offices Revisions to Rules of Practice before the Patent Trial and Appeal Board notice of proposed rulemaking [Docket No. PTO-P-2025-0025] requiring Inter Partes Review (IPR) filers to choose between district court litigation and IPR; and Federal policy relating to Patent and Trademark Office discretionary denials of IPR institution.
Foreign entity interest: Apotex Corp., in its 4Q 2024 Form LD-2, delisted all previously disclosed Foreign Entities following the purchase of Apotex Corp. and its direct and indirect parent corporations and affiliates by a domestic US company. Apotex Inc. exercises management over Apotex Corp. but holds no equity in, and provides no funding of, Apotex Corp. lobbying activities. Apotex Inc.'s interest in Apotex Corp. lobbying activities is limited to Apotex Corp.'s financial success in the US market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.